ZA200900379B - Human endogenous retrovirus polypeptide compositions and methods of use thereof - Google Patents

Human endogenous retrovirus polypeptide compositions and methods of use thereof

Info

Publication number
ZA200900379B
ZA200900379B ZA200900379A ZA200900379A ZA200900379B ZA 200900379 B ZA200900379 B ZA 200900379B ZA 200900379 A ZA200900379 A ZA 200900379A ZA 200900379 A ZA200900379 A ZA 200900379A ZA 200900379 B ZA200900379 B ZA 200900379B
Authority
ZA
South Africa
Prior art keywords
methods
polypeptide compositions
endogenous retrovirus
human endogenous
retrovirus polypeptide
Prior art date
Application number
ZA200900379A
Other languages
English (en)
Inventor
Mario Ostrowski
R Bradley Jones
Seth Rakoff-Nahoum
Douglas Nixon
Keith Garrison
Duncan Meiklejohn
Ashish Agrawal
Jack Lenz
Frederick M Hecht
Original Assignee
Univ California
David Gladstone Inst
Albert Einstein Coll Med
Mario Ostrowski
R Bradley Jones
Seth Rakoff-Nahoum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, David Gladstone Inst, Albert Einstein Coll Med, Mario Ostrowski, R Bradley Jones, Seth Rakoff-Nahoum filed Critical Univ California
Publication of ZA200900379B publication Critical patent/ZA200900379B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA200900379A 2006-07-21 2007-07-19 Human endogenous retrovirus polypeptide compositions and methods of use thereof ZA200900379B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83246506P 2006-07-21 2006-07-21

Publications (1)

Publication Number Publication Date
ZA200900379B true ZA200900379B (en) 2010-08-25

Family

ID=38957380

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200900379A ZA200900379B (en) 2006-07-21 2007-07-19 Human endogenous retrovirus polypeptide compositions and methods of use thereof

Country Status (15)

Country Link
US (2) US20080171061A1 (enExample)
EP (1) EP2046380A4 (enExample)
JP (1) JP2009544614A (enExample)
KR (1) KR20090060410A (enExample)
CN (1) CN101557823A (enExample)
AU (1) AU2007275693A1 (enExample)
BR (1) BRPI0714714A2 (enExample)
CA (1) CA2658393A1 (enExample)
IL (1) IL196516A0 (enExample)
MX (1) MX2009000659A (enExample)
NO (1) NO20090818L (enExample)
RU (1) RU2009106089A (enExample)
SG (1) SG173997A1 (enExample)
WO (1) WO2008011120A2 (enExample)
ZA (1) ZA200900379B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE045482T2 (hu) 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény
US20090297530A1 (en) * 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
EP2340851A4 (en) * 2008-09-18 2012-09-26 Univ Keio DIAGNOSTIC METHOD AND THERAPEUTIC METHOD FOR CANCER
WO2010053772A2 (en) 2008-10-29 2010-05-14 The Regents Of The University Of California Disease-associated antigens and methods of use thereof
EP2519539A4 (en) * 2009-12-28 2013-11-13 Ligocyte Pharmaceuticals Inc METHODS FOR STABILIZING VIRUS-LIKE PARTICULATE SOLUTIONS BASED ON INFLUENZA-INFLUENZA-VIRUSED VIRUSES
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition
IL330095A (en) 2012-01-26 2026-08-01 Vanda Pharmaceuticals Inc Tesimalta for use in the treatment of asynchronous circadian rhythm of cortisol
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US20160145348A1 (en) 2013-03-14 2016-05-26 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
EP4166161B1 (en) 2016-04-14 2026-03-04 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
JP7046016B2 (ja) 2016-06-30 2022-04-01 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｈｅｒｖ－ｅ反応性ｔ細胞受容体および使用方法
WO2018037042A1 (en) * 2016-08-23 2018-03-01 Aimvion A/S Novel immunostimulating peptides
WO2018129270A1 (en) 2017-01-05 2018-07-12 Fred Hutchinson Cancer Research Center Systems and methods to improve vaccine efficacy
EP3606550A2 (en) * 2017-04-03 2020-02-12 Neon Therapeutics, Inc. Protein antigens and uses thereof
US11351247B2 (en) 2017-09-01 2022-06-07 Inprother Aps Vaccine for use in the prophylaxis and/or treatment of a disease
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
WO2019143948A1 (en) 2018-01-18 2019-07-25 Fred Hutchinson Cancer Research Center Altering inflammatory states of immune cells in vivo by modulating cellular activation states
SG11202012653XA (en) 2018-06-19 2021-01-28 Biontech Us Inc Neoantigens and uses thereof
WO2020049169A1 (en) * 2018-09-06 2020-03-12 Centre Léon-Bérard Herv-k-derived antigens as shared tumor antigens for anti-cancer vaccine
US20220259617A1 (en) 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
WO2024108001A2 (en) * 2022-11-16 2024-05-23 The General Hospital Corporation Minimal human-derived virus-like particles and methods of use thereof for delivery of biomolecules
US20260035415A1 (en) * 2024-08-01 2026-02-05 Twilight Bioscience, Inc. Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
US20030162263A1 (en) * 2001-09-06 2003-08-28 Marc Dupuis Peptides derived from the superantigen (SAg) ENV protein of HERV-K18 and their use in obtaining SAG-inhibitory antibodies and in vaccination against SAG
AT411262B (de) * 2001-09-27 2003-11-25 Wolff Klaus Dr Humanes endogenes retrovirus
JP4822490B2 (ja) * 2001-12-07 2011-11-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 腫瘍形成形質転換に関連する内因性レトロウイルスポリペプチド
US20040096457A1 (en) * 2001-12-11 2004-05-20 Huber Brigitte T Treatment and prevention of ebv infection and ebv-associated disorders
EP1338606A1 (en) * 2002-02-22 2003-08-27 Magnus Von Knebel Doeberitz Nucleic Acid encoding an HERV-H polypeptide for diagnosing colorectal cancer
US20130108653A1 (en) * 2009-12-22 2013-05-02 Shervin Bahrami Bivalent molecules for hiv entry inhibition
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition

Also Published As

Publication number Publication date
WO2008011120A2 (en) 2008-01-24
US20080171061A1 (en) 2008-07-17
CA2658393A1 (en) 2008-01-24
RU2009106089A (ru) 2010-08-27
EP2046380A4 (en) 2013-05-01
BRPI0714714A2 (pt) 2013-04-09
CN101557823A (zh) 2009-10-14
IL196516A0 (en) 2011-08-01
AU2007275693A1 (en) 2008-01-24
SG173997A1 (en) 2011-09-29
KR20090060410A (ko) 2009-06-12
JP2009544614A (ja) 2009-12-17
US20130323279A1 (en) 2013-12-05
NO20090818L (no) 2009-04-17
MX2009000659A (es) 2009-06-08
EP2046380A2 (en) 2009-04-15
WO2008011120A3 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
IL196516A0 (en) Human endogenous retrovirus polypeptide compositions and methods of use thereof
IL262205A (en) Protein formulations and methods for their preparation
HRP20182133T1 (hr) Pripravci koji sadrže azelastin i postupci njihove upotrebe
SG2013054218A (en) Powdered protein compositions and methods of making same
EP2102237A4 (en) RECOMBINANT HUMAN FACTOR IX AND USE THEREOF
IL195161A0 (en) Pharmaceutical compositions of ropinirole and methods of use thereof
PT2099321T (pt) Composições de leite humano e métodos de fabrico e utilização das mesmas
PL3398606T3 (pl) Kompozycje otrzymane z mikroalg poprawiające zdrowie i wygląd skóry
IL189364A0 (en) Estrogen compositions and therapeutic methods of use thereof
PL2193142T3 (pl) Kompozycje i sposoby z zastosowaniem peptydów prowysepkowych i ich analogów
IL197501A0 (en) Modifications of cupredoxin derived peptides and methods of use thereof
IL190885A0 (en) Immunogenic compositions and methods of use
HRP20160902T1 (hr) Pripravci i postupci uporabe forbolskih estera
EP2234636A4 (en) FORMULATIONS OF STABILIZED PEPTIDES AND PROTEINS
BRPI0813000A2 (pt) Composições terapêuticas e uso das mesmas
PT2291654T (pt) Preparação e composição de proteínas inibidoras de interalfa do sangue
PL2601961T3 (pl) Kompozycje zawierające LAG-3 i terapeutyczne przeciwciała oraz ich zastosowania w leczeniu raka
EP2188309A4 (en) COMPOSITIONS BASED ON GELSOLIN FIXING AGENTS AND USES THEREOF
EP1940460A4 (en) OLIGOD DRO CYTEN MYELIN GLYCOPROTEIN COMPOSITIONS AND USES THEREOF
PL1890720T3 (pl) Kompozycje farmaceutyczne zawierające peptydy pochodzące z kazeiny i sposoby ich stosowania
EP2149601A4 (en) SOLUBILIZED AMNIOS COMPOSITION AND USE THEREOF
IL179962A0 (en) Compositions and methods of use of dimer digallates
ZA200710374B (en) Pharmaceutical compositions comprising casein derived peptides and methods of use thereof
IL185548A0 (en) Medical uses of 39-desmethoxyrapamycin and analogues thereof
IL177751A0 (en) Pharmaceutical composition of (+)-erythro-mefloquine and its use